DANONE (BSN.DE) Stock Fundamental Analysis
FRA:BSN - Deutsche Boerse Ag - FR0000120644 - Common Stock - Currency: EUR
Overall BSN gets a fundamental rating of 4 out of 10. We evaluated BSN against 56 industry peers in the Food Products industry. While BSN has a great profitability rating, there are quite some concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
BSN had positive earnings in each of the past 5 years.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
BSN's Return On Assets of 4.46% is fine compared to the rest of the industry. BSN outperforms 60.71% of its industry peers.
BSN has a Return On Equity of 11.34%. This is in the better half of the industry: BSN outperforms 60.71% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.58%, BSN is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.10%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROIC | 6.58% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
The Profit Margin of BSN (7.37%) is better than 64.29% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
Looking at the Operating Margin, with a value of 13.00%, BSN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
BSN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 49.70%, BSN is in the better half of the industry, outperforming 73.21% of the companies in the same industry.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BSN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BSN has less shares outstanding
BSN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.48 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.48, BSN perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
BSN has a debt to FCF ratio of 4.89. This is a neutral value as BSN would need 4.89 years to pay back of all of its debts.
BSN has a Debt to FCF ratio of 4.89. This is in the better half of the industry: BSN outperforms 69.64% of its industry peers.
BSN has a Debt/Equity ratio of 0.66. This is a neutral value indicating BSN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.66, BSN is in line with its industry, outperforming 41.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Altman-Z | 2.48 |
ROIC/WACC1.03
WACC6.4%
2.3 Liquidity
A Current Ratio of 0.93 indicates that BSN may have some problems paying its short term obligations.
With a Current ratio value of 0.93, BSN is not doing good in the industry: 76.79% of the companies in the same industry are doing better.
A Quick Ratio of 0.77 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio of 0.77. This is in the lower half of the industry: BSN underperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.54%.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
BSN shows a decrease in Revenue. In the last year, the revenue decreased by -0.88%.
BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
3.2 Future
The Earnings Per Share is expected to grow by 6.38% on average over the next years.
Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.05% on average per year.
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y6.38%
Revenue Next Year4.17%
Revenue Next 2Y3.95%
Revenue Next 3Y3.97%
Revenue Next 5Y3.05%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BSN is valuated rather expensively with a Price/Earnings ratio of 20.61.
Compared to the rest of the industry, the Price/Earnings ratio of BSN is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 28.79, BSN is valued a bit cheaper.
With a Price/Forward Earnings ratio of 19.09, BSN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than 62.50% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BSN to the average of the S&P500 Index (21.38), we can say BSN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.61 | ||
| Fwd PE | 19.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BSN is valued a bit more expensive than the industry average as 60.71% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.49 | ||
| EV/EBITDA | 11.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.59
PEG (5Y)N/A
EPS Next 2Y7.64%
EPS Next 3Y7.59%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.92%.
Compared to an average industry Dividend Yield of 3.23, BSN pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.51, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.92% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
BSN pays out 66.80% of its income as dividend. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP66.8%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
FRA:BSN (4/25/2025, 7:00:00 PM)
74.8
-0.36 (-0.48%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners54.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap50.83B
Analysts72.12
Price Target73.25 (-2.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.92% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP66.8%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.94%
PT rev (3m)5.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.75%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.61 | ||
| Fwd PE | 19.09 | ||
| P/S | 1.86 | ||
| P/FCF | 17.49 | ||
| P/OCF | 13.27 | ||
| P/B | 2.86 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.13 |
EPS(TTM)3.63
EY4.85%
EPS(NY)3.92
Fwd EY5.24%
FCF(TTM)4.28
FCFY5.72%
OCF(TTM)5.64
OCFY7.53%
SpS40.29
BVpS26.18
TBVpS-9.15
PEG (NY)2.59
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROCE | 11.27% | ||
| ROIC | 6.58% | ||
| ROICexc | 8.06% | ||
| ROICexgc | 68% | ||
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% | ||
| FCFM | 10.62% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Debt/EBITDA | 2.49 | ||
| Cap/Depr | 79.02% | ||
| Cap/Sales | 3.37% | ||
| Interest Coverage | 20.69 | ||
| Cash Conversion | 81.04% | ||
| Profit Quality | 144.05% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 2.48 |
F-Score7
WACC6.4%
ROIC/WACC1.03
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y6.38%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
Revenue Next Year4.17%
Revenue Next 2Y3.95%
Revenue Next 3Y3.97%
Revenue Next 5Y3.05%
EBIT growth 1Y2.24%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year38.47%
EBIT Next 3Y15.23%
EBIT Next 5Y10.44%
FCF growth 1Y11.98%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y11.24%
OCF growth 3Y3.31%
OCF growth 5Y2.15%